Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban for pulmonary arterial hypertension in systemic sclerosis and connective tissue disease
ACTRN12614000418673Phase 3Terminated
- Sponsor
- St Vincent's Hospital Melbourne
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) and systemic sclerosis (SSc) comparing Apixaban plus background PAH therapy with Placebo plus background PAH therapy (2 arms). Primary endpoint: Time to first clinical worsening. Started Sep 2014; status: terminated.
02
Drugs
apixaban
03
Conditions
pulmonary arterial hypertension (PAH)systemic sclerosis (SSc)
Beyond the preview
Go deeper on ACTRN12614000418673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000418673.